Protagonist Stock Analysis

PTGX -  USA Stock  

USD 43.14  0.67  1.58%

The current price rise of Protagonist Therapeutics may encourage investors to take a closer look at the company as it is trading at a share price of 43.14 on 629,475 in trading volume. The company management teams may have good odds in positioning the company resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.75. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Protagonist Therapeutics partners.
Please check Your Equity Center.

Search Stock Analysis 

 
Refresh
The Protagonist Therapeutics stock analysis report makes it easy to digest most publicly released information about Protagonist Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Protagonist stock analysis module also helps to analyze the Protagonist Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Protagonist Stock Analysis Notes

About 105.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.92. Protagonist Therapeutics had not issued any dividends in recent years. Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Protagonist Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. To find out more about Protagonist Therapeutics contact Dinesh Patel at 510 474-0170 or learn more at www.protagonist-inc.com.

Protagonist Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Protagonist Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Protagonist Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Protagonist Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 28.63 M. Net Loss for the year was (66.15 M) with profit before overhead, payroll, taxes, and interest of 28.63 M.
Protagonist Therapeutics currently holds about 305.81 M in cash with (72.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.98.
Protagonist Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from www.nasdaq.com: Company News for Jun 14, 2021 - Nasdaq

Protagonist Therapeutics Upcoming and Recent Events

Earnings reports are used by Protagonist Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protagonist Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Protagonist Largest EPS Surprises

Earnings surprises can significantly impact Protagonist Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-03-12
2018-12-31-0.474-0.57-0.09620 
2018-08-07
2018-06-30-0.3033-0.41-0.106735 
2018-05-09
2018-03-31-0.24-0.36-0.1250 
View All Earnings Estimates

Protagonist Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Protagonist Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protagonist Therapeutics backward and forwards among themselves. Protagonist Therapeutics' institutional investor refers to the entity that pools money to purchase Protagonist Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares6.6 M170.2 M
Bvf IncCommon SharesM102.5 M
Rtw Investments LpCommon Shares3.5 M90.8 M
Blackrock IncCommon SharesM77.7 M
Consonance Capital Management LpCommon Shares2.7 M70.2 M
Johnson Johnson InnovatioCommon Shares2.4 M63.4 M
Farallon Capital Management LlcCommon Shares2.4 M62.8 M
Note, although Protagonist Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Protagonist Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Protagonist Therapeutics's market, we take the total number of its shares issued and multiply it by Protagonist Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Protagonist Profitablity

Protagonist Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Protagonist Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Protagonist Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Protagonist Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Protagonist Therapeutics' profitability requires more research than a typical breakdown of Protagonist Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (231.07) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (225.36) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.25.
Last ReportedProjected for 2021
Return on Investment(34.93) (37.69) 
Return on Average Assets(27.60) (29.78) 
Return on Average Equity(36.79) (39.70) 

Management Efficiency

The entity has return on total asset (ROA) of (16.82) % which means that it has lost $16.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (36.79) %, meaning that it created substantial loss on money invested by shareholders. Protagonist Therapeutics management efficiency ratios could be used to measure how well protagonist therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -37.69 in 2021. Return on Average Assets is likely to drop to -29.78 in 2021. Protagonist Therapeutics Total Assets are fairly stable at the moment as compared to the past year. Protagonist Therapeutics reported Total Assets of 324.47 Million in 2020. Current Assets is likely to rise to about 340.5 M in 2021, whereas Return on Average Assets are likely to drop (29.78)  in 2021.

Technical Drivers

As of the 20th of June, Protagonist Therapeutics holds the Coefficient Of Variation of 694.54, semi deviation of 2.98, and Risk Adjusted Performance of 0.0996. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protagonist Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Protagonist Therapeutics, which can be compared to its competitors. Please check Protagonist Therapeutics variance and potential upside to decide if Protagonist Therapeutics is priced some-what accurately, providing market reflects its current price of 43.14 per share. Given that Protagonist Therapeutics has jensen alpha of 0.5658, we recommend you to check out Protagonist Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

Protagonist Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Protagonist Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator. View also all equity analysis or get more info about mesa adaptive moving average overlap studies indicator.

Protagonist Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protagonist Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protagonist Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protagonist Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bryan Giraudo over three weeks ago via Macroaxis 
Acquisition by Bryan Giraudo of 18000 shares of Protagonist Therapeutics subject to Rule 16b-3
Donald Kalkofen over three months ago via Macroaxis 
Acquisition by Donald Kalkofen of 55000 shares of Protagonist Therapeutics subject to Rule 16b-3
Sarah Noonberg over three months ago via Macroaxis 
Exercise or conversion by Sarah Noonberg of 3700 shares of Protagonist Therapeutics subject to Rule 16b-3
Dinesh Patel over three months ago via Macroaxis 
Exercise or conversion by Dinesh Patel of 13000 shares of Protagonist Therapeutics subject to Rule 16b-3
Odowd Sarah A over six months ago via Macroaxis 
Acquisition by Odowd Sarah A of 30000 shares of Protagonist Therapeutics subject to Rule 16b-3
Bryan Giraudo over six months ago via Macroaxis 
Acquisition by Bryan Giraudo of 12000 shares of Protagonist Therapeutics subject to Rule 16b-3
Chaitan Khosla over six months ago via Macroaxis 
Exercise or conversion by Chaitan Khosla of 2499 shares of Protagonist Therapeutics subject to Rule 16b-3
Bryan Giraudo over a year ago via Macroaxis 
Acquisition by Bryan Giraudo of 15000 shares of Protagonist Therapeutics subject to Rule 16b-3
Dinesh Patel over a year ago via Macroaxis 
Bona fide gift to Dinesh Patel of 2000 shares of Protagonist Therapeutics subject to Section 16
Chaitan Khosla over a year ago via Macroaxis 
Acquisition by Chaitan Khosla of 5000 shares of Protagonist Therapeutics subject to Rule 16b-3
Dinesh Patel over a year ago via Macroaxis 
Exercise or conversion by Dinesh Patel of 10000 shares of Protagonist Therapeutics subject to Rule 16b-3
Dinesh Patel over a year ago via Macroaxis 
Exercise or conversion by Dinesh Patel of 18344 shares of Protagonist Therapeutics subject to Rule 16b-3

Protagonist Therapeutics Technical and Predictive Indicators

Protagonist Therapeutics Forecast Models

Protagonist Therapeutics time-series forecasting models is one of many Protagonist Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Protagonist Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Protagonist Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Protagonist Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Protagonist shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Protagonist Therapeutics. By using and applying Protagonist Stock analysis, traders can create a robust methodology for identifying Protagonist entry and exit points for their positions.
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Protagonist Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Current Protagonist Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Protagonist analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Protagonist analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
47.14Strong Buy7Odds
Protagonist Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Protagonist analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Protagonist stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Protagonist Therapeutics, talking to its executives and customers, or listening to Protagonist conference calls.
Protagonist Analyst Advice Details

Protagonist Stock Analysis Indicators

Protagonist Therapeutics stock analysis indicators help investors evaluate how Protagonist Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Protagonist Therapeutics shares will generate the highest return on investment. By understating and applying Protagonist Therapeutics stock analysis, traders can identify Protagonist Therapeutics position entry and exit signals to maximize returns.
Quick Ratio7.69
Fifty Two Week Low14.16
Revenue Growth107.80%
Shares Short Prior Month2.87M
Average Daily Volume Last 10 Day549.24k
Average Daily Volume In Three Month322.93k
Shares Percent Shares Out6.92%
Gross Margins100.00%
Short Percent Of Float8.81%
Forward Price Earnings-18.13
Float Shares27.92M
Fifty Two Week High42.30
Enterprise Value To Ebitda-15.47
Fifty Day Average32.20
Two Hundred Day Average26.69
Enterprise Value To Revenue34.44
Please check Your Equity Center. Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Protagonist Therapeutics Stock analysis

When running Protagonist Therapeutics price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Protagonist Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.